Blog
RSS FeedPosted by Michael Wonder on 11 Jun 2018
Rheumatoid arthritis: few indications of the benefits of certain biologics over others
6 June 2018 - Still no long-term studies and little direct comparisons of biologics/first-time also first-line therapy examined. ...
Posted by Michael Wonder on 04 Jun 2018
English translation of IQWiG’s updated General Methods now available
4 June 2018 - New chapters on HTA reports addressing topics proposed by the public and on the assessment of ...
Posted by Michael Wonder on 27 Apr 2018
IQWiG in dialogue on 15 June 2018: Do the new "estimand" strategies threaten the standards of benefit assessment?
26 April 2018 - Registration now possible/discussion about current method proposals of the EMA. ...
Posted by Michael Wonder on 01 Mar 2018
Dupilumab in atopic dermatitis: indication of added benefit in adults
1 March 2018 - Significant benefits in terms of symptoms and especially in quality of life/dossier provides meaningful data. ...
Posted by Michael Wonder on 21 Feb 2018
Industry's experiences with the scientific advice offered by the Federal Joint Committee within the early benefit assessment of pharmaceuticals in Germany
19 February 2018 - Optional scientific advice for the early benefit assessment of pharmaceuticals is offered by the German decision maker, ...
Posted by Michael Wonder on 18 Jan 2018
Early benefit assessments: the 220th dossier evaluation completed at the turn of the year
18 January 2018 - Oncology remains by far the most common indication. ...
Posted by Michael Wonder on 16 Jan 2018
In a nutshell 2017: new issue with facts and graphics from the IQWiG
15 January 2018 - Third issue with focus on quality assurance/numerous graphs illustrate work results. ...
Posted by Michael Wonder on 16 Jan 2018
Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: studies of direct comparison are useful
4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...
Posted by Michael Wonder on 15 Jan 2018
German watchdog calls for direct comparison of cancer immunotherapies
16 January 2018 - Germany’s drug assessment body has criticized a lack of data directly comparing drugs in a promising ...
Posted by Michael Wonder on 09 Jan 2018
Finding RCTs of new drugs: searches in trial registries require specific adaptations
5 January 2018 - In their article in the Journal of Clinical Epidemiology, Marco Knelangen, Elke Hausner, Sibylle Sturtz, and ...
Posted by Michael Wonder on 03 Sep 2017
Nivolumab in squamous cell carcinoma in the head and neck area: additional benefit for certain patients
1 September 2017 - Significant benefit for patients with progression during or shortly after platinum-based therapy. ...
Posted by Michael Wonder on 03 Jul 2017
IQWiG finds no additional benefit for tenofovir alafenamide fumarate in chronic hepatitis B
3 July 2017 - The anti-viral medicine tenofovir alafenamide fumarate has been used in various combinations since 2015 in HIV ...
Posted by Michael Wonder on 01 Jun 2017
Secukinumab and ixekizumab in psoriasis: significant additional benefit for certain patients
1 June 2017 - The manufacturer of secukinumab has applied for a new benefit assessment as new scientific evidence emerges. ...
Posted by Michael Wonder on 16 May 2017
Pembrolizumab in non-small-cell lung cancer: a hint of considerable added benefit
15 May 2017 - Patients in the relevant subpopulation of the analysed study survived longer. ...
Posted by Michael Wonder on 25 Apr 2017
IQWiG in Dialogue 2017: programme is now online
24 April 2017 - The first IQWiG methods paper (version 1.0) was published on March 1, 2005. Since then the IQWiG ...